Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05136014 | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model(OS-TUMOVASC) | unknown | — | 200 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05132218 | Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer(EFLRWR) | unknown | — | 180 | Peking University Cancer Hospital & Institute |
| 1 |
| Nov 24, 2021 |
| clinicaltrials |
| NCT05132777 | Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 155 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Nov 24, 2021 | clinicaltrials |
| NCT04405674 | Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | unknown | Phase 2 | 120 | Shanghai Chest HospitalOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT02824952 | Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC | unknown | Phase 2 | 40 | Shaare Zedek Medical CenterOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT04984148 | Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC | unknown | — | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05098990 | Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC | unknown | Phase 4 | 328 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT05097417 | Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer | unknown | N/A | 110 | Shanghai 10th People's HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05094167 | Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients | unknown | N/A | 46 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT03236675 | Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients | unknown | — | 60 | Exosome Diagnostics, Inc.INDUSTRY | 1 | Sep 30, 2021 | clinicaltrials |
| NCT05055167 | Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05055583 | Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC | unknown | Phase 2 | 30 | Tang-Du HospitalOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | unknown | Phase 1 | 80 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02330367 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC | unknown | Phase 1 / Phase 2 | 368 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04291092 | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04755738 | Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer(MWA) | unknown | Phase 2 | 234 | Qianfoshan HospitalOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT05034055 | Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer(SKYROCKET) | unknown | Phase 2 | 45 | Yonsei UniversityOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04943029 | Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC(NEOSUN) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT05031533 | Dose-painting Radiation for LA-NSCLC(DPRLC) | unknown | N/A | 46 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04778800 | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) | unknown | N/A | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04586465 | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC(DYNAPET) | unknown | Phase 2 | 23 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT00759382 | Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study. | unknown | — | 340 | European Lung Cancer Working PartyOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04465942 | Immunotherapy in Lung Cancer: Treatment After IO Cessation. | unknown | — | 300 | European Lung Cancer Working PartyOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04964479 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 375 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 20, 2021 | clinicaltrials |
| NCT02731001 | Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer(PRONTOX) | unknown | N/A | 98 | Technische Universität DresdenOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT05010330 | Identify Prognostic Biomarkers of Lung Cancer | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT05008861 | Gut Microbiota Reconstruction for NSCLC Immunotherapy | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04682327 | Gut Microbiota and Cancer Immunotherapy Response | unknown | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT05005468 | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.(CAMFA-L) | unknown | Phase 2 | 61 | Shanghai Chest HospitalOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04697446 | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | unknown | — | 279 | Blueprint Medicines CorporationINDUSTRY | 3 | Aug 10, 2021 | clinicaltrials |
| NCT04998474 | FRAME-001 Personalized Vaccine in NSCLC | unknown | Phase 2 | 15 | Frame Pharmaceuticals B.V.INDUSTRY | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04982549 | A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC | unknown | Phase 2 | 35 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04990063 | Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 20 | suhaichuanOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04867564 | Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy | unknown | — | 100 | Military Institute od Medicine National Research InstituteOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT03893461 | Coagulation System In STereotactic Radiotherapy Of NSCLC(CISTRON) | unknown | — | 110 | Odense University HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | unknown | Phase 2 | 64 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02448797 | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation(EVIDENCE) | unknown | Phase 3 | 320 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03439215 | PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer(PFROST) | unknown | Phase 2 | 20 | Fondazione Ricerca TraslazionaleOTHER | 1 | Jul 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 26, 2021source: clinicaltrials